Skip to content

About
Mission

Guiding Principles

Collaborations & Partnerships

Solid Team

Management

Board of Directors

Founders

Working at Solid

Culture

Benefits

Open Positions
Our Science
Pipeline & Programs

Pipeline

Clinical Trials

Scientific Publications & Presentations

Infrastructure

Manufacturing
Patient & Caregiver Resources
Duchenne Muscular Dystrophy

What is Duchenne?

Why Gene Transfer?

Patient Stories

Friedreich’s Ataxia

What is Friedreich’s Ataxia?

What is Frataxin?

For Patients

CPVT

What is CPVT?

Patient Stories

Strength in Community

Engaging the Community

Charity Partners

Insights & News

Resources & Policies

Expanded Access Policy

Clinical Trials
Partner With Us
Investors & Media
Overview & News

Overview

Press Releases

Presentations

Events

Governance & Financials

Governance Documents

Committee Charters

Committee Composition

SEC Filings

Stock Information

Stock Quote Chart

Historical Price Lookup

Analyst Coverage

Investor Resources

Investor FAQs

Contact Solid Biosciences

Email Alerts

Efficacy and Safety of a Novel Investigational AAV FXN Gene Therapy (SGT-212) for the Treatment of Friedreich’s Ataxia

Search

Recent Posts

Letter to the Duchenne Community
Letter to the Duchenne Community
Letter to the FA Community
Letter to the Duchenne Community
Letter to the CPVT Community

Recent Comments

No comments to show.

Stay Connected

Linkedin X-twitter

Join our team of experts to advance treatments for patients

Contact Us
Privacy Policy
Terms & Conditions

Contact Us
Privacy Policy
Terms & Conditions

© 2024 Solid Biosciences Inc. All Rights Reserved.

Solid Biosciences Inc., is a Charlestown, MA based life science company focused on advancing a portfolio of neuromuscular and cardiac programs.

The characterization of the discovery and development efforts on this website, as well as the expectations associated with them, are reflective of the current state of development and may change as the Company progresses.